Skip to main content

Thank you for visiting nature.com. You are using a browser version with limited support for CSS. To obtain the best experience, we recommend you use a more up to date browser (or turn off compatibility mode in Internet Explorer). In the meantime, to ensure continued support, we are displaying the site without styles and JavaScript.

  • Paper
  • Published:

Long-term outcome of detectable PSA levels after radical prostatectomy

Prostate Cancer and Prostatic Diseases volume 8, pages 163–166 (2005)Cite this article

Abstract

Detectable prostate-specific antigen levels (PSA) following radical prostatectomy (RP) are believed to represent treatment failure. In this retrospective review, we characterize long-term PSA outcomes following RP (n=204) in a nonreferral hospital performed between 1984 and 1994. With an average follow-up of 10 y, 90 (44%) patients developed a PSA recurrence: 15 (17%) died of prostate cancer despite hormonal intervention, 39 (43%) responded to hormonal therapy with stable remission and 36 (40%) were observed without intervention. Following RP many patients may have a detectable PSA that does not require treatment. PSA doubling time (<12 months) was the best predictor of disease progression.

This is a preview of subscription content, access via your institution

Access options

Buy this article

  • Purchase on Springer Link
  • Instant access to full article PDF
Buy now

Prices may be subject to local taxes which are calculated during checkout

Figure 1
Figure 2

Similar content being viewed by others

References

  1. Catalona WJ et al. Measurement of prostate-specific antigen in serum as a screening test for prostate cancer. N Engl J Med 1991; 324: 1156–1161.

    Article  CAS  Google Scholar 

  2. Potosky AL, Miller BA, Albertsen PC, Kramer BS . The role of increasing detection in the rising incidence of prostate cancer. JAMA 1995; 273: 548–552.

    Article  CAS  Google Scholar 

  3. Eastham JA, Scardino PT . Radical Prostatectomy. In: Walsh PC, Retik AB, Vaughn Jr ED, Wein AJ (eds). Campbell's Urology, 8th ed, WB Saunders, Philadelphia, PA, 2002, pp 3094–3101.

    Google Scholar 

  4. Partin AW et al. Combination of prostate-specific antigen, clinical stage, and Gleason score to predict pathological stage of localized prostate cancer. A multi-institutional update. JAMA 1997; 277: 1445–1451.

    Article  CAS  Google Scholar 

  5. Kattan MW et al. A preoperative nomogram for disease recurrence following radical prostatectomy for prostate cancer. J Natl Cancer Inst 1998; 90: 766–771.

    Article  CAS  Google Scholar 

  6. Trapasso JG, deKernion JB, Smith RB, Dorey F . The incidence and significance of detectable levels of serum prostate specific antigen after radical prostatectomy. J Urol 1994; 152: 1821–1825.

    Article  CAS  Google Scholar 

  7. Partin AW et al. Evaluation of serum prostate-specific antigen velocity after radical prostatectomy to distinguish local recurrence from distant metastases. Urology 1994; 43: 649–659.

    Article  CAS  Google Scholar 

  8. Patel A, Dorey F, Franklin J, deKernion JB . Recurrence patterns after radical retropubic prostatectomy: clinical usefulness of prostate specific antigen doubling times and log slope prostate specific antigen. J Urol 1997; 158: 1441–1445.

    Article  CAS  Google Scholar 

  9. Cheng L et al. Correlation of margin status and extraprostatic extension with progression of prostate carcinoma. Cancer 1999; 86: 1775–1782.

    Article  CAS  Google Scholar 

  10. Jhaveri FM et al. Declining rates of extracapsular extension after radical prostatectomy: evidence for continued stage migration. J Clin Oncol 1999; 17: 3167–3172.

    Article  CAS  Google Scholar 

  11. Stamey TA et al. Histological and clinical findings in 896 consecutive prostates treated only with radical retropubic prostatectomy: epidemiologic significance of annual changes. J Urol 1998; 160: 2412–2417.

    Article  CAS  Google Scholar 

  12. Amling CL et al. Influence of prostate-specific antigen testing on the spectrum of patients with prostate cancer undergoing radical prostatectomy at a large referral practice. Mayo Clin Proc 1998; 73: 401–406.

    Article  CAS  Google Scholar 

  13. Catalona WJ, Smith DS, Ratliff TL, Basler JW . Detection of organ-confined prostate cancer is increased through prostate-specific antigen-based screening. JAMA 1993; 270: 948–954.

    Article  CAS  Google Scholar 

  14. Han M et al. Era specific biochemical recurrence free survival following radical prostatectomy for clinically localized prostate cancer. J Urol 2001; 166: 416–419.

    Article  CAS  Google Scholar 

  15. Gerber GS et al. Results of radical prostatectomy in men with clinically localized prostate cancer. JAMA 1996; 276: 615–619.

    Article  CAS  Google Scholar 

  16. Lu-Yao GL, Yao SL . Population-based study of long-term survival in patients with clinically localised prostate cancer. Lancet 1997; 349: 906–910.

    Article  CAS  Google Scholar 

  17. Messing E et al. Immediate hormonal therapy compared with observation after radical prostatectomy and pelvic lymphadenectomy in men with node positive prostate cancer. N Engl J Med 1999; 341: 1781–1788.

    Article  CAS  Google Scholar 

  18. The Medical Research Council Prostate Cancer Working Party Investigators Group . Immediate versus deferred treatment for advanced prostatic cancer: initial results of the Medical Research Council trial. Br J Urol 1997; 79: 235–246.

    Article  Google Scholar 

  19. Myers RP et al. Hormonal treatment at time of radical retropubic prostatectomy for stage D1 prostate cancer: results of long-term followup. J Urol 1992; 147: 910–915.

    Article  CAS  Google Scholar 

  20. Koch MO et al. Characterization and predictors of prostate specific antigen progression rates after radical retropubic prostatectomy. J Urol 2000; 164: 749–753.

    Article  CAS  Google Scholar 

  21. Pound CR et al. Natural History of progression after PSA elevation following radical prostatectomy. JAMA 1999; 281: 1591–1597.

    Article  CAS  Google Scholar 

  22. Pruthi RS, Johnstone I, Tu IP, Stamey TA . Prostate-specific antigen doubling times in patients who have failed radical prostatectomy: correlation with histologic characteristics of the primary cancer. Urology 1997; 49: 737–742.

    Article  CAS  Google Scholar 

  23. Soergel TM et al. Accuracy of predicting long-term prostate specific antigen outcome based on early prostate specific antigen recurrence results after radical prostatectomy. J Urol 2001; 166: 2198–2201.

    Article  CAS  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Department of Urology, UC Irvine Medical Center, Orange, California, USA

    T E Ahlering & D W Skarecky

Authors
  1. T E Ahlering
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. D W Skarecky
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to T E Ahlering.

Rights and permissions

Reprints and permissions

About this article

Cite this article

Ahlering, T., Skarecky, D. Long-term outcome of detectable PSA levels after radical prostatectomy. Prostate Cancer Prostatic Dis 8, 163–166 (2005). https://doi.org/10.1038/sj.pcan.4500788

Download citation

  • Received:

  • Revised:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1038/sj.pcan.4500788

Keywords

This article is cited by

Search

Advanced search

Quick links